We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-1.18%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$496M
AUM Growth
+$22M
(+4.6%)
Cap. Flow
+$34.5M
Cap. Flow
% of AUM
6.96%
Top 10 Holdings %
Top 10 Hldgs %
10.47%
Holding
461
New
27
Increased
142
Reduced
189
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$3.17M |
| 2 |
MPLX
MPLX
|
+$3.04M |
| 3 |
BlackRock Limited Duration Income Trust
BLW
|
+$2.79M |
| 4 |
ABDC
Alcentra Capital Corp
ABDC
|
+$1.98M |
| 5 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$1.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
+$6.67M |
| 2 |
ECC
Eagle Point Credit Company
ECC
|
+$5.43M |
| 3 |
ANDX
Andeavor Logistics LP
ANDX
|
+$2.66M |
| 4 |
BlackRock Floating Rate Income Strategies Fund
FRA
|
+$2.25M |
| 5 |
MVC
MVC Capital, Inc.
MVC
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.1% |
| 2 | Real Estate | 16.28% |
| 3 | Energy | 14.42% |
| 4 | Healthcare | 8.59% |
| 5 | Materials | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Ascendis Pharma A/S
ASND
$16.8B
| $202K | 0.04% |
2,098
-116
| -5% | -$12.9K |
|
252
Franklin FTSE India ETF
FLIN
$2.71B
| $202K | 0.04% |
9,109
-19,968
| -69% | -$436K |
|
253
Wave Life Sciences
WVE
$1.16B
| $202K | 0.04% |
9,839
-548
| -5% | -$12.6K |
|
|
BLUE
254
DELISTED
bluebird bio
BLUE
| $198K | 0.04% |
166
-10
| -6% | -$15.3K |
|
255
MeiraGTx Holdings
MGTX
$1.18B
| $196K | 0.04% |
12,311
-686
| -5% | -$16K |
|
256
TG Therapeutics
TGTX
$8.7B
| $195K | 0.04% |
34,803
-1,938
| -5% | -$13.5K |
|
|
ESPR
257
DELISTED
Esperion Therapeutics
ESPR
| $189K | 0.04% |
5,144
-286
| -5% | -$11.3K |
|
|
BOLD
258
DELISTED
Audentes Therapeutics, Inc
BOLD
| $188K | 0.04% |
6,682
-371
| -5% | -$12.7K |
|
259
Insmed
INSM
$23.1B
| $187K | 0.04% |
10,609
-591
| -5% | -$11.4K |
|
260
Regenxbio
RGNX
$658M
| $186K | 0.04% |
5,232
-292
| -5% | -$11.8K |
|
261
Rocket Pharmaceuticals
RCKT
$363M
| $182K | 0.04% |
15,663
-872
| -5% | -$10.8K |
|
262
Alector
ALEC
$173M
| $181K | 0.04% |
12,526
-698
| -5% | -$12.6K |
|
263
Dianthus Therapeutics
DNTH
$5.78B
| $181K | 0.04% |
1,100
-61
| -5% | -$11.6K |
|
264
Corbus Pharmaceuticals
CRBP
$175M
| $180K | 0.04% |
1,229
-69
| -5% | -$12K |
|
265
Voyager Therapeutics
VYGR
$195M
| $180K | 0.04% |
10,430
-581
| -5% | -$12.2K |
|
266
CytomX Therapeutics
CTMX
$740M
| $179K | 0.04% |
24,301
-1,353
| -5% | -$13.3K |
|
|
UBX
267
DELISTED
Unity Biotechnology
UBX
| $177K | 0.04% |
2,894
-161
| -5% | -$11.4K |
|
|
ATNX
268
DELISTED
Athenex, Inc. Common Stock
ATNX
| $173K | 0.03% |
710
-39
| -5% | -$12.8K |
|
269
Assembly Biosciences
ASMB
$523M
| $172K | 0.03% |
1,454
-81
| -5% | -$12.3K |
|
|
SRNE
270
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $172K | 0.03% |
80,214
-4,468
| -5% | -$10.4K |
|
|
AKCA
271
DELISTED
Akcea Therapeutics Inc
AKCA
| $171K | 0.03% |
11,111
-619
| -5% | -$13.2K |
|
|
BHVN
272
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $168K | 0.03% |
4,026
-223
| -5% | -$9.42K |
|
273
Atara Biotherapeutics
ATRA
$73.7M
| $163K | 0.03% |
462
-26
| -5% | -$9.7K |
|
|
FTSV
274
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $154K | 0.03% |
23,979
-1,335
| -5% | -$11K |
|
|
MYOV
275
DELISTED
Myovant Sciences Ltd.
MYOV
| $152K | 0.03% |
29,180
-1,619
| -5% | -$12K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q3 2019 Portfolio in Review
As of Q3 2019, Virtus ETF Advisers held 461 positions worth $496M, up 4.6% from $474M the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Virtus ETF Advisers deployed $34.5M of net new capital in Q3 2019, opening 27 new positions and adding to 142 existing holdings. Its largest new stake was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.
By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 24% a quarter earlier, followed by Real Estate and Energy.
On the sell side, the largest reduction was TriplePoint Venture Growth BDC, an estimated $813K trimmed.
- Virtus ETF Advisers's largest Q3 2019 buy was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.
- Virtus ETF Advisers added most to MPLX in Q3 2019, an estimated $3.04M increase.
- Virtus ETF Advisers's biggest Q3 2019 reduction was TriplePoint Venture Growth BDC, cutting an estimated $813K.
- Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2019, selling an estimated $6.67M.
- Virtus ETF Advisers's ten largest holdings make up 10% of its $496M portfolio in Q3 2019.
- Virtus ETF Advisers opened 27 new positions and closed 26 in Q3 2019.
- Virtus ETF Advisers's portfolio value rose 4.6% quarter-over-quarter to $496M.
Based on Virtus ETF Advisers's 13F filing for Q3 2019, filed 12 Nov 2019.